The US Food and Drug Administration (FDA) has granted clearance for SIRPant Immunotherapeutics’ investigational new drug (IND) application enabling initiation of a first-in-human Phase I clinical trial of SIRPant-M to treat relapsed refractory non-Hodgkin lymphoma.

SIRPant plans to conduct this multi-centre study in the third quarter across five sites in the US.

Patients with relapsed refractory non-Hodgkin lymphoma will be administered with SIRPant-M, an autologous SIRPαlow activated macrophage immunotherapy to treat aggressive tumours.

SIRPant R&D vice-president Nathanael McCurley said: “Leveraging recent findings in macrophage biology, we developed a first-in-class cell therapy, SIRPant-M, to initiate adaptive immune responses against cancerous cells without requiring prior cancer-associated antigen identification.

“SIRPant-M employs a proprietary cocktail, PhagoAct, to license macrophages to drive tumour neo-antigen-specific polyclonal T cell and antibody responses, thus targeting cancer cells through multiple avenues simultaneously.”

SIRPant-M also brings in long-lasting polyclonal immune memory against cancer by mobilising the cellular as well as humoral arms of the immune system.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also plans to file a second IND for SIRPant-M to treat solid tumours, initially targeting head and neck cancers.

SIRPant president and CEO Robert Towarnicki said: “This initial study will enroll relapsed refractory non-Hodgkin lymphoma patients who are ineligible for or previously failed approved therapeutic regimens.”